ClinicalTrials.gg
CompletedNCT04285229Updated Apr 14, 2023Results posted

A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

A Phase 3 interventional study of Ixekizumab and Placebo in Spondyloarthritis, sponsored by Eli Lilly and Company. Completed at 19 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-14.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Spondylarthritis with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Spondylarthritis · China.

Enrollment
6th of 10
147 · median 149
Started
2020
with 1 other
Phase 3
3 of 17
none open now
Registered
8th of 17
by date
Lead sponsor
1 of 17
Eli Lilly and Company

Among the 17 studies in Spondylarthritis with a site in China, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 8th registered.

Spondylarthritis

203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.

Browse Spondylarthritis studies →

Open to participants now

6 of the 17 studies in Spondylarthritis with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Spondylarthritis studies recruiting now, 20 (54%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Spondylarthritis with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).

03

Conditions studied

  • Spondyloarthritis

Keywords

  • Ankylosing spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an established diagnosis of radiographic axial spondyloarthritis (r-xSpA) with sacroiliitis defined radiographically according to the modified New York criteria.
  • Participants have a history of back pain ≥3 months with age at onset \<45 years.
  • Biologic naïve or have had prior treatment with 1 tumor necrosis factor (TNF) inhibitor.
  • Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs.
  • Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Have total ankylosis of the spine.
  • Have recently received a within 12 weeks or have had a vaccination with Bacillus Calmette-Guerin (BCG) within the past year.
  • Have an ongoing or serious infection within the last 12 weeks.
  • Have a compromised immune system.
  • Have any other serious and/or uncontrolled diseases.
  • Have either a current diagnosis or a recent history of malignant disease.
  • Have had major surgery within 8 weeks of baseline, or will require surgery during the study.
  • Are pregnant or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Ixekizumab

    Participants received Ixekizumab during the double-blind and extended treatment periods (i.e.,) starting dose of 160 milligrams (mg) Ixekizumab in the beginning week followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection. No treatments were administered during the follow-up period.

    Drug: Ixekizumab

  • Placebo comparator
    Placebo

    Participants received placebo every four weeks (Q4W) by subcutaneous (SC) injection during the double-blind period. During the extension period, they received starting dose of 160 milligrams (mg) Ixekizumab in the beginning week followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection. No treatments were administered during follow-up period.

    Drug: Ixekizumab · Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY2439821

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response in Biological Disease-modifying Antirheumatic Drug (bDMARD)-naïve Participants

    ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving an ASAS40 Response

    ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

    Time frame: Week 16

  2. Percentage of Participants Achieving an ASAS20 Response

    ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

    Time frame: Week 16

  3. Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

    ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Least Square (LS) mean was determined by mixed-model repeated measures (MMRM) with treatment, baseline C-reactive protein (CRP) status, Tumor necrosis factor (TNF) inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  4. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Response

    The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  5. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

    The BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. The BASFI is composed with 10 questions to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of AS participants. Participants respond to each question using an NRS scale (range 0 to 10). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  6. Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)

    MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) were scored for bone marrow edema. A single DVU has 18 scoring units, and each has score of 0 or 1, bringing the maximum total score to 414, the sum ranges from 0 to 414 with higher scores reflecting worse disease. Scoring was performed by central readers. LS mean was determined by ANCOVA with factors for treatment, baseline CRP status, TNF inhibitors experience, and baseline value.

    Time frame: Baseline, Week 16

  7. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

    SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health. LS mean was determined by MMRM with factors for treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  8. Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score

    SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health. LS mean was determined by MMRM with factors for treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  9. Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

    High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  10. Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)

    BASMI is a combined index comprising of 5 clinical measurements of spinal mobility in patients with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their AS. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  11. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

    The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  12. Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score

    The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with factors for treatment, baseline CRP status, TNF inhibitors experience, and baseline value.

    Time frame: Baseline, Week 16

  13. Number of Participants With Anterior Uveitis

    Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

    Time frame: Baseline through Week 16

  14. Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score

    ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of NSAID (150 mg/day diclofenac) was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). The total score range is from 0 to 100, higher the score greater the NSAID intake and 0 represents no intake at all. A negative change from baseline indicates less NSAID consumption.

    Time frame: Baseline, Week 52

  15. Percentage of Participants With Anti-Ixekizumab Antibodies

    A treatment emergent - antidrug antibody (TE-ADA) positive participant is defined as: a) a participant with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

    Time frame: Week 16

  16. Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)

    Pharmacokinetics (PK): Steady-state trough serum concentration of Ixekizumab at week 16.

    Time frame: Week 16

07

Results

Posted Jun 28, 2022

Participant flow

The study was designed to be conducted in three periods: * Double-Blind Treatment Period (Week 0 to Week 16) * Extended Treatment Period (Week 16 to Week 52) * Follow-up Period (at least 4 weeks and up to 12 weeks after the date of the participant's last visit)

Double-Blind Treatment Period
Participant flow — Double-Blind Treatment Period
MilestonePlaceboIxekizumab 80mg Q4WPlacebo/Ixekizumab 80mg Q4W - Extended Treatment PeriodIxekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment PeriodPlacebo - Follow-up PeriodIxekizumab 80mg Q4W - Follow-up Period
Started73740000
Received at least one dose of study drug73740000
Completed71740000
Not completed200000
Withdrew: Withdrawal by subject200000
Extended Treatment Period
Participant flow — Extended Treatment Period
MilestonePlaceboIxekizumab 80mg Q4WPlacebo/Ixekizumab 80mg Q4W - Extended Treatment PeriodIxekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment PeriodPlacebo - Follow-up PeriodIxekizumab 80mg Q4W - Follow-up Period
Started00707200
Completed00696400
Not completed001800
Withdrew: Withdrawal by subject000700
Withdrew: Adverse event000100
Withdrew: Physician decision001000
Follow-up Period
Participant flow — Follow-up Period
MilestonePlaceboIxekizumab 80mg Q4WPlacebo/Ixekizumab 80mg Q4W - Extended Treatment PeriodIxekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment PeriodPlacebo - Follow-up PeriodIxekizumab 80mg Q4W - Follow-up Period
Started00001135
Completed00000123
Not completed0000112
Withdrew: Adverse event000014
Withdrew: Withdrawal by subject000005
Withdrew: Covid-19000002
Withdrew: Physician decision000001

Outcome measures

PrimaryPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response in Biological Disease-modifying Antirheumatic Drug (bDMARD)-naïve Participants

ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response in Biological Disease-modifying Antirheumatic Drug (bDMARD)-naïve Participants
Percentage of ParticipantsPlaceboIxekizumab 80mg Q4W
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response in Biological Disease-modifying Antirheumatic Drug (bDMARD)-naïve Participants7.840.9
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.64 · 95% CI 2.68 to 21.76
SecondaryPercentage of Participants Achieving an ASAS40 Response

ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an ASAS40 Response
Percentage of ParticipantsPlaceboIxekizumab 80mg Q4W
Percentage of Participants Achieving an ASAS40 Response8.237.8
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.40 · 95% CI 2.42 to 16.90
SecondaryPercentage of Participants Achieving an ASAS20 Response

ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an ASAS20 Response
Percentage of ParticipantsPlaceboIxekizumab 80mg Q4W
Percentage of Participants Achieving an ASAS20 Response35.659.5
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Regression, Logistic · p = 0.006 · Odds ratio (or): 2.58 · 95% CI 1.31 to 5.09
SecondaryChange From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Least Square (LS) mean was determined by mixed-model repeated measures (MMRM) with treatment, baseline C-reactive protein (CRP) status, Tumor necrosis factor (TNF) inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
Units on a scalePlaceboIxekizumab 80mg Q4W
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-0.19 ± 0.103-1.33 ± 0.100
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.14 · 95% CI -1.38 to -0.90
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Response

The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Response
Units on a scalePlaceboIxekizumab 80mg Q4W
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Response-0.90 ± 0.231-2.39 ± 0.226
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.49 · 95% CI -2.04 to -0.94
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

The BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. The BASFI is composed with 10 questions to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of AS participants. Participants respond to each question using an NRS scale (range 0 to 10). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
Units on a scalePlaceboIxekizumab 80mg Q4W
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)-0.49 ± 0.237-1.36 ± 0.230
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = 0.002 · Ls mean difference: -0.87 · 95% CI -1.43 to -0.32
SecondaryChange From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)

MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) were scored for bone marrow edema. A single DVU has 18 scoring units, and each has score of 0 or 1, bringing the maximum total score to 414, the sum ranges from 0 to 414 with higher scores reflecting worse disease. Scoring was performed by central readers. LS mean was determined by ANCOVA with factors for treatment, baseline CRP status, TNF inhibitors experience, and baseline value.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)
Units on a scalePlaceboIxekizumab 80mg Q4W
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)-0.93 ± 1.550-8.65 ± 1.507
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · ANCOVA · p = <0.001 · Ls mean difference: -7.72 · 95% CI -10.85 to -4.60
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health. LS mean was determined by MMRM with factors for treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
Units on a scalePlaceboIxekizumab 80mg Q4W
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score1.23 ± 0.7403.85 ± 0.716
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = 0.001 · Ls mean difference: 2.62 · 95% CI 1.07 to 4.17
SecondaryChange From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score

SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health. LS mean was determined by MMRM with factors for treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score
Units on a scalePlaceboIxekizumab 80mg Q4W
Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score-0.06 ± 1.0270.45 ± 1.003
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = 0.660 · Ls mean difference: 0.51 · 95% CI -1.77 to 2.79
SecondaryChange From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · milligram per liter (mg/L)
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
milligram per liter (mg/L)PlaceboIxekizumab 80mg Q4W
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)2.65 ± 1.349-10.10 ± 1.312
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Ls mean difference: -12.75 · 95% CI -15.91 to -9.59
SecondaryChange From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)

BASMI is a combined index comprising of 5 clinical measurements of spinal mobility in patients with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their AS. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)
Units on a scalePlaceboIxekizumab 80mg Q4W
Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)0.06 ± 0.093-0.30 ± 0.090
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.36 · 95% CI -0.57 to -0.15
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
Units on a scalePlaceboIxekizumab 80mg Q4W
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)-1.06 ± 0.349-1.77 ± 0.361
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = 0.086 · Ls mean difference: -0.72 · 95% CI -1.54 to 0.10
SecondaryChange From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score

The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with factors for treatment, baseline CRP status, TNF inhibitors experience, and baseline value.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score
units on a scalePlaceboIxekizumab 80mg Q4W
Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score-1.31 ± 1.021-6.98 ± 0.986
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · ANCOVA · p = <0.001 · Ls mean difference: -5.67 · 95% CI -7.71 to -3.62
SecondaryNumber of Participants With Anterior Uveitis

Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

Time frame:
Baseline through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Anterior Uveitis
ParticipantsPlaceboIxekizumab 80mg Q4W
Number of Participants With Anterior Uveitis00
SecondaryChange From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score

ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of NSAID (150 mg/day diclofenac) was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). The total score range is from 0 to 100, higher the score greater the NSAID intake and 0 represents no intake at all. A negative change from baseline indicates less NSAID consumption.

Time frame:
Baseline, Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score
Units on a scalePlacebo/Ixekizumab 80mg Q4W - Extended Treatment PeriodIxekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment Period
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score-30.71 ± 46.481-26.13 ± 41.384
SecondaryPercentage of Participants With Anti-Ixekizumab Antibodies

A treatment emergent - antidrug antibody (TE-ADA) positive participant is defined as: a) a participant with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-Ixekizumab Antibodies
Percentage of participantsPlaceboIxekizumab 80mg Q4W
Percentage of Participants With Anti-Ixekizumab Antibodies4.113.5
SecondaryPharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)

Pharmacokinetics (PK): Steady-state trough serum concentration of Ixekizumab at week 16.

Time frame:
Week 16
Reported as:
Geometric mean · microgram per milliliters (µg/mL)
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)
microgram per milliliters (µg/mL)Ixekizumab 80mg Q4W
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)3.89 ± 52

Adverse events

Collected over Baseline to Follow-up (Up To 64 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/73 (0%)1/73 (1.4%)17/73 (23.3%)
Ixekizumab 80mg Q4W0/74 (0%)2/74 (2.7%)31/74 (41.9%)
Placebo/Ixekizumab 80mg Q4W - Extended Treatment Period0/70 (0%)6/70 (8.6%)43/70 (61.4%)
Ixekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment Period0/72 (0%)4/72 (5.6%)41/72 (56.9%)
Placebo - Follow-up Period0/1 (0%)0/1 (0%)0/1 (0%)
Ixekizumab 80mg Q4W - Follow-up Period0/135 (0%)1/135 (0.7%)11/135 (8.1%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlaceboIxekizumab 80mg Q4WPlacebo/Ixekizumab 80mg Q4W - Extended Treatment PeriodIxekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment PeriodPlacebo - Follow-up PeriodIxekizumab 80mg Q4W - Follow-up Period
Male genital tract tuberculosisInfections and infestations0/650/641/620/620/10/119
Auricular haematomaInjury, poisoning and procedural complications0/730/741/700/720/10/135
Brain contusionInjury, poisoning and procedural complications0/730/741/700/720/10/135
Hand fractureInjury, poisoning and procedural complications0/730/741/700/720/10/135
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/730/741/700/720/10/135
Varicose veinVascular disorders0/730/741/700/720/10/135
Pulmonary tuberculosisInfections and infestations0/730/740/701/720/10/135
Urinary tract infectionInfections and infestations0/730/740/701/720/10/135
Vestibular neuronitisInfections and infestations0/730/740/701/720/10/135
Benign connective tissue neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/730/740/701/720/10/135
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboIxekizumab 80mg Q4WPlacebo/Ixekizumab 80mg Q4W - Extended Treatment PeriodIxekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment PeriodPlacebo - Follow-up PeriodIxekizumab 80mg Q4W - Follow-up Period
Injection site reactionGeneral disorders2/735/7420/7025/720/10/135
Upper respiratory tract infectionInfections and infestations11/739/7419/7016/720/15/135
Vaginal infectionInfections and infestations0/80/101/80/100/10/16
Pelvic fluid collectionReproductive system and breast disorders0/80/101/80/100/10/16
HyperuricaemiaMetabolism and nutrition disorders2/736/747/704/720/14/135
Hepatic function abnormalHepatobiliary disorders2/734/746/702/720/10/135
HyperlipidaemiaMetabolism and nutrition disorders0/732/744/706/720/10/135
LeukopeniaBlood and lymphatic system disorders0/736/743/702/720/10/135
Weight increasedInvestigations1/731/745/703/720/11/135
Alanine aminotransferase increasedInvestigations2/735/741/701/720/10/135

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)PlaceboIxekizumab 80mg Q4WTotal
Mean34.4 ± 8.9833.5 ± 8.8933.9 ± 8.92
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIxekizumab 80mg Q4WTotal
Female81018
Male6564129
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboIxekizumab 80mg Q4WTotal
Hispanic or Latino000
Not Hispanic or Latino7374147
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboIxekizumab 80mg Q4WTotal
American Indian or Alaska Native000
Asian7374147
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)PlaceboIxekizumab 80mg Q4WTotal
China7374147
08

Study locations

19 sites
  • Afflilated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong 518020, China
  • 1st Hospital affiliated to Medical College of Shantou Univer
    Shantou, Guangzhou 515041, China
  • Wuhan Union Hospital
    Wuhan, Hubei 430022, China
  • Wu Han Tongji Hospital
    Wuhan, Hubei 430030, China
  • ZhuZhou Central Hospital
    ZhuZhou, Hunan 412007, China
  • The First Affiliated Hospital of Baotou Medical College
    Baotou, Inner Mongolia 014000, China
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210000, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi 337000, China
  • HuaShan Hospital Affiliated To Fudan University
    Shanghai, Shanghai 20040, China
  • West China Hospital Sichuan University
    Chengdu, Sichuan 610041, China
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Urumqi, Xinjiang 830001, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • Peking University First Hospital
    Beijing, 100034, China
  • Beijing Hospital
    Beijing, 100730, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Mar 2021, 11 months.

Results were first posted in Jun 2022, 1 year 2 months after primary completion. A results delay was requested in Mar 2022.

Of 12 phase 3 interventional studies under Spondylarthritis, half reached primary completion within 21 months of starting (the median); a quarter within 15 and three quarters within 37. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2020
First posted
Feb 26, 2020
StartActual
Apr 10, 2020
Primary completionActual
Mar 31, 2021
CompletionActual
Mar 17, 2022
Results delay requested
Mar 10, 2022
Results first posted
Jun 28, 2022
Last update
Apr 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04285229
Responsible party
Sponsor
First posted
Feb 26, 2020
Start date
Apr 10, 2020
Primary completion
Mar 31, 2021
Completion
Mar 17, 2022
Results posted
Jun 28, 2022
Last update
Apr 14, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion